Oncology CME

  • 25% OFF W/ CODE: SAVINGS25
    FEATURED

    Cancer Management CME Online Bundle: Comprehensive Review – Journal Summaries – $500 Amazon Gift Card

    The Cancer Management CME Online Bundle includes:
    • From CMEinfo Radiation Oncology – A Comprehensive Review led by Christopher G. Willett, MD, and featuring lectures for an all-encompassing clinical update
    • From Practical Reviews A one-year subscription, including our FREE mobile app
    • A $500 Amazon.com gift card
    • Unbiased content to help you prep for the boards and stay current without the need for travel or time away from your practice
    • Instant online access to key clinical updates to improve overall patient care
    • The opportunity to earn up to 82.25 AMA PRA Category 1 Credits combined

    Target Audience: Oncologists (especially Radiation Oncologists).

    See full details chevron_right
    • Cost: $1595$1196
    • Credit hours: 82.25
    • CME credits awarded by: Oakstone Publishing, LLC.
    • Format: On-Demand Online, Online Video
    • Material last updated: November 30, 2016
    • Expiration of CME credit: November 30, 2019
  • 25% OFF W/ CODE: SAVINGS25
    FEATURED

    The Brigham and Dana-Farber Board Review in Oncology

    This Oncology CME course will help you earn CME credits, MOC points, and prepare for medical Oncology board exams. 

    Topics covered in this course include:
    • Advances in Cancer Drug Development 
    • Symptom Management in Patients with Cancer
    • Infections in Cancer Patients
    • Breast Cancer: Risk Factors, Genetics, Screening and Prevention
    • Head and Neck Cancer
    • Prostate Cancer

    After completing this course physicians will be able to: 
    • Apply recommended oncology guidelines in clinical practice
    • Perform differential diagnosis of complex oncologic disorders
    • Identify and apply current therapeutic options for oncologic disorders
    • Evaluate and interpret up-to-date literature relevant to oncology
    • Apply knowledge gained to the ABIM certification/recertification oncology examinations

    Target Audience: Oncologists

     

    See full details chevron_right
    • Cost: $1295$971
    • Credit hours: 31.75
    • CME credits awarded by: Oakstone Publishing, LLC
    • Format: On-Demand Online, Online Video, Online Audio, Audio CD
    • Material last updated: April 15, 2020
    • Expiration of CME credit: April 15, 2023
  • FREE GIFT CARD

    Audio Digest Clinical Compendium: Oncology

    Free gift card with purchase!

    Own a collection of hand-selected lectures in the Oncology field. Clinical Compendium allows you unlimited access to 150 accredited lectures, presented by experts from the country’s leading medical institutions. Every lecture is accompanied by educational objectives, a written summary, and CME test questions.

    To make your access easy and efficient, we’ve grouped all these lectures into relevant clinical topics. Each topic is conveniently delivered in its own playlist to help you identify the content you are most interested in listening to at any time.

    CME credit is available for each lecture, with the potential to earn up to 119.25 AMA PRA Category 1 Credits™.

    See full details chevron_right
    • Cost: $1199
    • Credit hours: 119.25
    • CME credits awarded by: 3 years from date of publication
    • Format: On-Demand Online, Online Audio
    • Material last updated: Continuously updated
    • Expiration of CME credit: 3 years from date of publication
  • FEATURED

    The Audio Digest Oncology Board Review

    Get a free gift card with purchase as well as:

    • 55 lectures available on CDs and MP3s
    • Course content based on ABIM requirements
    • Appropriate for preparing for Certification or Recertification or as a comprehensive review of the specialty
    • Access to all lectures from your computer or the Audio Digest Mobile App
    • Earn 36 AMA PRA Category 1 Credits™
    See full details chevron_right
    • Cost: $1499
    • Credit hours: 36
    • CME credits awarded by: Accreditation Council for Continuing Medical Education (ACCME)
    • Format: On-Demand Online, Online Audio
    • Material last updated: Every 3 years
    • Expiration of CME credit: 3 years from date of publication
  • 20% OFF W/ CODE: SPOOKY
    FEATURED

    BoardVitals Hematology and Oncology CME Board Review

    The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 CreditsTM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

    The BoardVitals Hematology and Oncology CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Hematology and Oncology test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

     

    Target Audience: Hematologists and Oncologists

    See full details chevron_right
    • Cost: $599$479
    • Credit hours: 27
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FREE

    Treating Oncology Patients During COVID-19

    Activity Description / Statement of Need: The COVID-19 pandemic has led to unprecedented changes in health care delivery worldwide, affecting the way that nearly every medical specialty can safely practice. As with other fields of medicine, oncology has its own challenges in navigating the pandemic. Based on pre-pandemic estimates, 1.8 million new cancer diagnoses would be expected in 2020, equating to approximately 5,000 new cancer diagnoses per day. Evidence thus far suggests that COVID-19 is associated with significantly more complications and a higher risk of death in patients with cancer or with a history of cancer. Furthermore, patients with cancer have also been shown to have a higher COVID-19 infection rate than the general population, suggesting increased susceptibility, potentially due to immunosuppression, comorbidities, or poor health status related to cancer or its treatment. Based on these data, oncology specialists are said to be fighting “a war on two fronts” by balancing the risks of COVID-19 transmission and acquisition with the risks of delayed cancer diagnosis and treatment. This represents an unmet need among oncology practitioners as they navigate this new health care landscape.

    Target Audience:

    Healthcare professionals, including medical oncologists; radiation oncologists; surgical oncologists; surgeons; radiologists; nuclear medicine specialists; nurse practitioners and physician assistants who practice in oncology; and other healthcare providers who manage cancer.

    By the end of the session the participant will be able to:

    • Recall the symptoms of COVID-19 infection and best practices for screening patients, health care providers, and staff in the oncology setting.
    • Develop a plan to provide oncology care in the setting of the COVID-19 pandemic.
    • Describe the risks of delaying cancer diagnosis and treatment against the risk of COVID-19 exposure and infection.
    • See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 09/22/2020
    • Expiration of CME credit: 09/22/2022
  • FREE

    Addressing skeletal-related events in prostate cancer

    Each year, an estimated 170,000 cases of prostate cancer are diagnosed. Although early prostate cancer may be cured with surgery or radiation therapy, more than 50% of men will experience recurrence after definitive treatment. The use of androgen deprivation therapy (ADT) for intermediate-risk, high-risk, and recurrent prostate cancer has greatly increased in the last 15 years, extending 10-year survival by nearly 25% compared with observation alone. New treatment options for advanced prostate cancer have further improved survival and increased the number of patients living with non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC). Despite the established improvements in survival associated with hormonal treatments, ADT has been associated with well-characterized negative effects on bone health. Indeed, bone metastases and subsequent skeletal-related events (SREs) are the primary driver of both morbidity and mortality among people with CRPC. In a study of 2234 men aged 65 years or older with a diagnosis of CRPC, 40% experienced SREs over a median follow-up of 10.6 months. Maintaining bone health in patients with CRPC requires routine monitoring and proactive management.

    Target Audience:

    The following healthcare professionals: urologists, medical and radiation oncologists, primary care physicians, nuclear medicine specialists and radiologists, and endocrinologists; physician assistants, nurse practitioners, and pharmacists who treat prostate cancer; and any other healthcare professionals who commonly care for patients with prostate cancer.

    By the end of the session the participant will be able to:

    • Recall the relative efficacy and safety of presently available agents used to for bone health and fracture prevention in patients with prostate cancer
    • Describe the identification and management of disease and intervention adverse effects on patients
    • Using details in a patient case, recommend an appropriate pharmacotherapeutic treatment plan for the purpose of preventing SREs in patients with prostate cancer
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/31/2020
    • Expiration of CME credit: 07/31/2022
  • FREE

    Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly–Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

    Metastatic Melanoma: Novel Approaches discusses the epidemiology, causes, clinical features, pathogenesis and immunotherapy in the treatment of metastatic melanoma.

    By the end of Metastatic Melanoma: Novel Approaches, you will be able to:
    • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
    • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Describe emerging (investigational) therapies for metastatic melanoma
    • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

    Target Audience:
    Oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 4, 2017
    • Expiration of CME credit: December 4, 2019
  • FREE

    Advances in Treating Triple-Negative Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies

    Over a quarter million women and almost 2,700 men in the U.S. are diagnosed with breast cancer each year, and it is the second leading cause of cancer death in women. The prognosis associated with breast has improved in the last few decades due in larger part to earlier detection. Detection at the loco-regional stage is associated with a five-year overall survival (OS) rate of ≥ 85% in contrast to 27% for distant or metastatic breast cancer (MBC).

    Because it is not curable, the goals of care in MBC are: palliation of symptoms, improvement of quality-of-life, and extension of survival. Hormone receptor positivity has traditionally conferred a better prognosis. In contrast, the presence the human epidermal growth factor receptor 2 (HER2) is associated with a more negative prognosis. Finally, there remains a basal-like group lacking in those markers, miscellaneously labeled triple-negative (TNBC), with some cancers observed to be more aggressive, but with the overall population similar in prognosis to hormone-positive breast cancer, owing to TNBC’s heterogenous nature.

    Target Audience:

    The following healthcare professionals: Medical oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with breast cancer.

    By the end of the session the participant will be able to:

    • Describe the prognostic and treatment implications of TN status in the diagnosis and treatment of MBC.
    • Describe treatment options presently available for TN MBC, including safety, and apply them to patient cases using evidence-based medicine.
    • Describe emerging treatment options presently available for TN MBC, their mechanisms of action and safety, and anticipated place in therapy.
    • Discuss barriers patients with TN MBC experience in attempting to access care, including burden of disease and adverse consequences of therapy, and propose ways to ameliorate them.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 05/20/2020
    • Expiration of CME credit: 05/20/2021
  • FREE

    Oncology Patients at High Risk of Bone Fracture: Advances in Pharmacotherapy

    The use of androgen deprivation therapy for prostate cancer has greatly increased in the last 15 years. Adjuvant aromatase inhibitor (AI) therapy is a common treatment in postmenopausal women with hormone receptor positive breast cancer. Bone fractures are of particular concern in these patents, given their association with increased mortality in prostate cancer and breast cancer patients.

    By the end of Oncology Patients at High Risk of Bone Fracture, you will be able to:
    • Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
    • Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
    Identify present pharmacotherapeutic treatments for management of a patient receiving • AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
    • Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case

    Target Audience:
    Oncologists, primary care physicians, and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology, endocrinology and internal medicine; and any other healthcare professionals who commonly care for patients with breast cancer or prostate cancer.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 17, 2017
    • Expiration of CME credit: November 17, 2019